Literature DB >> 35999374

Novel 3D magnetic resonance fingerprinting radiomics in adult brain tumors: a feasibility study.

Charit Tippareddy1, Louisa Onyewadume2, Andrew E Sloan3, Gi-Ming Wang4, Nirav T Patil5, Siyuan Hu5, Jill S Barnholtz-Sloan6,7, Rasim Boyacıoğlu1, Vikas Gulani8, Jeffrey Sunshine1, Mark Griswold1,5, Dan Ma1, Chaitra Badve9.   

Abstract

OBJECTIVES: To test the feasibility of using 3D MRF maps with radiomics analysis and machine learning in the characterization of adult brain intra-axial neoplasms.
METHODS: 3D MRF acquisition was performed on 78 patients with newly diagnosed brain tumors including 33 glioblastomas (grade IV), 6 grade III gliomas, 12 grade II gliomas, and 27 patients with brain metastases. Regions of enhancing tumor, non-enhancing tumor, and peritumoral edema were segmented and radiomics analysis with gray-level co-occurrence matrices and gray-level run-length matrices was performed. Statistical analysis was performed to identify features capable of differentiating tumors based on type, grade, and isocitrate dehydrogenase (IDH1) status. Receiver operating curve analysis was performed and the area under the curve (AUC) was calculated for tumor classification and grading. For gliomas, Kaplan-Meier analysis for overall survival was performed using MRF T1 features from enhancing tumor region.
RESULTS: Multiple MRF T1 and T2 features from enhancing tumor region were capable of differentiating glioblastomas from brain metastases. Although no differences were identified between grade 2 and grade 3 gliomas, differentiation between grade 2 and grade 4 gliomas as well as between grade 3 and grade 4 gliomas was achieved. MRF radiomics features were also able to differentiate IDH1 mutant from the wild-type gliomas. Radiomics T1 features for enhancing tumor region in gliomas correlated to overall survival (p < 0.05).
CONCLUSION: Radiomics analysis of 3D MRF maps allows differentiating glioblastomas from metastases and is capable of differentiating glioblastomas from metastases and characterizing gliomas based on grade, IDH1 status, and survival. KEY POINTS: • 3D MRF data analysis using radiomics offers novel tissue characterization of brain tumors. • 3D MRF with radiomics offers glioma characterization based on grade, IDH1 status, and overall patient survival.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Glioblastoma; Glioma; Magnetic resonance fingerprinting; Metastasis; Radiomics

Year:  2022        PMID: 35999374     DOI: 10.1007/s00330-022-09067-w

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  17 in total

1.  Magnetic resonance fingerprinting with quadratic RF phase for measurement of T2 * simultaneously with δf , T1 , and T2.

Authors:  Charlie Yi Wang; Simone Coppo; Bhairav Bipin Mehta; Nicole Seiberlich; Xin Yu; Mark Alan Griswold
Journal:  Magn Reson Med       Date:  2018-10-30       Impact factor: 4.668

2.  Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer.

Authors:  Alice C Yu; Chaitra Badve; Lee E Ponsky; Shivani Pahwa; Sara Dastmalchian; Matthew Rogers; Yun Jiang; Seunghee Margevicius; Mark Schluchter; William Tabayoyong; Robert Abouassaly; Debra McGivney; Mark A Griswold; Vikas Gulani
Journal:  Radiology       Date:  2017-02-10       Impact factor: 11.105

3.  Rapid Radial T1 and T2 Mapping of the Hip Articular Cartilage With Magnetic Resonance Fingerprinting.

Authors:  Martijn A Cloos; Jakob Assländer; Batool Abbas; James Fishbaugh; James S Babb; Guido Gerig; Riccardo Lattanzi
Journal:  J Magn Reson Imaging       Date:  2018-12-24       Impact factor: 4.813

4.  Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brain Tumors.

Authors:  Peter de Blank; Chaitra Badve; Deborah Rukin Gold; Duncan Stearns; Jeffrey Sunshine; Sara Dastmalchian; Krystal Tomei; Andrew E Sloan; Jill S Barnholtz-Sloan; Adam Lane; Mark Griswold; Vikas Gulani; Dan Ma
Journal:  Pediatr Neurosurg       Date:  2019-08-15       Impact factor: 1.162

5.  Texture analysis of diffusion weighted imaging for the evaluation of glioma heterogeneity based on different regions of interest.

Authors:  Shan Wang; Meng Meng; Xue Zhang; Chen Wu; Ru Wang; Jiangfen Wu; Muhammad Umair Sami; Kai Xu
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

6.  Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR Fingerprinting.

Authors:  Johannes Haubold; Aydin Demircioglu; Marcel Gratz; Martin Glas; Karsten Wrede; Ulrich Sure; Gerald Antoch; Kathy Keyvani; Mathias Nittka; Stephan Kannengiesser; Vikas Gulani; Mark Griswold; Ken Herrmann; Michael Forsting; Felix Nensa; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-06       Impact factor: 9.236

7.  MR Fingerprinting and ADC Mapping for Characterization of Lesions in the Transition Zone of the Prostate Gland.

Authors:  Ananya Panda; Verena C Obmann; Wei-Ching Lo; Seunghee Margevicius; Yun Jiang; Mark Schluchter; Indravadan J Patel; Dean Nakamoto; Chaitra Badve; Mark A Griswold; Irina Jaeger; Lee E Ponsky; Vikas Gulani
Journal:  Radiology       Date:  2019-07-23       Impact factor: 11.105

8.  MR fingerprinting for rapid quantification of myocardial T1 , T2 , and proton spin density.

Authors:  Jesse I Hamilton; Yun Jiang; Yong Chen; Dan Ma; Wei-Ching Lo; Mark Griswold; Nicole Seiberlich
Journal:  Magn Reson Med       Date:  2016-04-01       Impact factor: 4.668

9.  Radiomic analysis of magnetic resonance fingerprinting in adult brain tumors.

Authors:  Sara Dastmalchian; Ozden Kilinc; Louisa Onyewadume; Charit Tippareddy; Debra McGivney; Dan Ma; Mark Griswold; Jeffrey Sunshine; Vikas Gulani; Jill S Barnholtz-Sloan; Andrew E Sloan; Chaitra Badve
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-09-26       Impact factor: 9.236

10.  Glioma: application of whole-tumor texture analysis of diffusion-weighted imaging for the evaluation of tumor heterogeneity.

Authors:  Young Jin Ryu; Seung Hong Choi; Sang Joon Park; Tae Jin Yun; Ji-Hoon Kim; Chul-Ho Sohn
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.